The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity

doi:10.1084/jem.167.3.1067

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Havell, E. A.
	Articles by North, R. J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Havell, E. A.
	Articles by North, R. J.


Social Bookmarking

	What's this?

ARTICLES

The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity

EA Havell, W Fiers and RJ North
Trudeau Institute, Saranac Lake, New York 12983.

The ability of murine recombinant tumor necrosis factor (rTNF) and natural TNF in tumor-necrotizing serum (TNS) to cause regression of the SA1 sarcoma was investigated. We found that to cause regression of a 9- d SA1 sarcoma, near lethal quantities of rTNF and TNS had to be given to the host. However, even at these highly toxic doses, rTNF was not reliable at causing complete tumor regression. On the other hand, both types of TNF were reliable at causing a tumor hemorrhagic reaction that resulted in the destruction of greater than 75% of the tumor's center in 24 h. The TNF-induced hemorrhagic reaction involved the development of numerous petechial hemorrhages in the tumor's vascular bed, which apparently resulted from destruction of the tumor's blood vessels. It was possible to follow the development of the hemorrhagic reaction against time after giving rTNF or TNS by measuring the intratumor extravasation of 51Cr-labeled syngeneic red cells. According to this method, TNF-induced intratumor hemorrhaging was in progress within 1 h of giving TNF and continued for about a 6-h period. However, the hemorrhagic reaction was greatly reduced and complete regression of the rim of the living tumor tissue that survived hemorrhagic necrosis failed to occur, if SA1 sarcoma was growing in T cell-deficient (TXB) mice. This indicates that the TNF-induced hemorrhagic reaction is partly dependent, and the tumor regression that follows is completely dependent on host immunocompetence. This suggests in turn, that rTNF does not directly destroy SA1 tumor cells in vivo, even though it was shown that it can destroy SA1 tumor cells in vitro. This interpretation is supported by the additional findings that rTNF was no more therapeutic against a 3-d (3-mm) SA1 than against a 9-d (8-mm) SA1, and was no more therapeutic when injected directly into the tumor than when injected intravenously. Lastly it was possible to completely inhibit the ability of rTNF and TNS to cause tumor hemorrhagic necrosis and regression by infusing the host with a monospecific, polyvalent anti- rTNF antibody that neutralized the cytotoxic action of rTNF in vitro.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Murugaiyan, G., Agrawal, R., Mishra, G. C., Mitra, D., Saha, B. (2006). Functional Dichotomy in CD40 Reciprocally Regulates Effector T Cell Functions. J. Immunol. 177: 6642-6649 [Abstract] [Full Text]
Buhtoiarov, I. N., Lum, H. D., Berke, G., Sondel, P. M., Rakhmilevich, A. L. (2006). Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects. J. Immunol. 176: 309-318 [Abstract] [Full Text]
Rowinsky, E. K. (2005). Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents. JCO 23: 9394-9407 [Abstract] [Full Text]
Ghobrial, I. M., Witzig, T. E., Adjei, A. A. (2005). Targeting Apoptosis Pathways in Cancer Therapy. CA Cancer J Clin 55: 178-194 [Abstract] [Full Text]
Wu, T. H., Pabin, C. N., Qin, Z., Blankenstein, T., Philip, M., Dignam, J., Schreiber, K., Schreiber, H. (2004). Long-Term Suppression of Tumor Growth by TNF Requires a Stat1- and IFN Regulatory Factor 1-Dependent IFN-{gamma} Pathway but Not IL-12 or IL-18. J. Immunol. 172: 3243-3251 [Abstract] [Full Text]
Schwamberger, G., Hammerl, P., Ferber, E., Freudenberg, M., Galanos, C. (2003). TNF revisited: TNF-independent antitumor activity in sera of mice sensitized with Propionibacterium acnes and challenged with lipopolysaccharide. J. Leukoc. Biol. 74: 1056-1063 [Abstract] [Full Text]
Bellnier, D. A., Gollnick, S. O., Camacho, S. H., Greco, W. R., Cheney, R. T. (2003). Treatment with the Tumor Necrosis Factor-{alpha}-Inducing Drug 5,6-Dimethylxanthenone-4-Acetic Acid Enhances the Antitumor Activity of the Photodynamic Therapy of RIF-1 Mouse Tumors. Cancer Res. 63: 7584-7590 [Abstract] [Full Text]
Naka, T., Sugamura, K., Hylander, B. L., Widmer, M. B., Rustum, Y. M., Repasky, E. A. (2002). Effects of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Alone and in Combination with Chemotherapeutic Agents on Patients' Colon Tumors Grown in SCID Mice. Cancer Res. 62: 5800-5806 [Abstract] [Full Text]
Frese, S., Brunner, T., Gugger, M., Uduehi, A., Schmid, R. A. (2002). Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J. Thorac. Cardiovasc. Surg. 123: 168-174 [Abstract] [Full Text]
Ghamande, S., Hylander, B. L, Oflazoglu, E., Lele, S., Fanslow, W., Repasky, E. A (2001). Recombinant CD40 Ligand Therapy Has Significant Antitumor Effects on CD40-positive Ovarian Tumor Xenografts Grown in SCID Mice and Demonstrates an Augmented Effect with Cisplatin. Cancer Res. 61: 7556-7562 [Abstract] [Full Text]
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., Kim, K. J. (2001). Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4. J. Immunol. 166: 4891-4898 [Abstract] [Full Text]
Clauss, M., Sunderkotter, C., Sveinbjornsson, B., Hippenstiel, S., Willuweit, A., Marino, M., Haas, E., Seljelid, R., Scheurich, P., Suttorp, N., Grell, M., Risau, W. (2001). A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97: 1321-1329 [Abstract] [Full Text]
Walczak, H., Bouchon, A., Stahl, H., Krammer, P. H. (2000). Tumor Necrosis Factor-related Apoptosis-inducing Ligand Retains Its Apoptosis-inducing Capacity on Bcl-2- or Bcl-xL-overexpressing Chemotherapy-resistant Tumor Cells. Cancer Res. 60: 3051-3057 [Abstract] [Full Text]
Nagane, M., Pan, G., Weddle, J. J., Dixit, V. M., Cavenee, W. K., Huang, H.-J. S. (2000). Increased Death Receptor 5 Expression by Chemotherapeutic Agents in Human Gliomas Causes Synergistic Cytotoxicity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Vitro and in Vivo. Cancer Res. 60: 847-853 [Abstract] [Full Text]
Gliniak, B., Le, T. (1999). Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo Is Enhanced by the Chemotherapeutic Agent CPT-11. Cancer Res. 59: 6153-6158 [Abstract] [Full Text]
Langley, R. R., Russell, J., Eppihimer, M. J., Alexander, S. J., Gerritsen, M., Specian, R. D., Granger, D. N. (1999). Quantification of murine endothelial cell adhesion molecules in solid tumors. Am. J. Physiol. Heart Circ. Physiol. 277: H1156-H1166 [Abstract] [Full Text]
Joseph, W. R., Cao, Z., Mountjoy, K. G., Marshall, E. S., Baguley, B. C., Ching, L.-M. (1999). Stimulation of Tumors to Synthesize Tumor Necrosis Factor-{{alpha}} in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid: A Novel Approach to Cancer Therapy. Cancer Res. 59: 633-638 [Abstract] [Full Text]
Zhai, Y., Ni, J., Jiang, G.-w., Lu, J., Xing, L., Lincoln, C., Carter, K. C., Janat, F., Kozak, D., Xu, S., Rojas, L., Aggarwal, B. B., Ruben, S., Li, L.-y., Gentz, R., Yu, G.-l. (1999). VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 13: 181-189 [Abstract] [Full Text]
Nakajima, A., Kodama, T., Morimoto, S., Azuma, M., Takeda, K., Oshima, H., Yoshino, S.-i., Yagita, H., Okumura, K. (1998). Antitumor Effect of CD40 Ligand: Elicitation of Local and Systemic Antitumor Responses by IL-12 and B7. J. Immunol. 161: 1901-1907 [Abstract] [Full Text]
Beretich, G. R. Jr., Carter, P. B., Havell, E. A. (1998). Roles for Tumor Necrosis Factor and Gamma Interferon in Resistance to Enteric Listeriosis. Infect. Immun. 66: 2368-2373 [Abstract] [Full Text]
Beg, A. A., Baltimore, D. (1996). An Essential Role for NF-kappa B in Preventing TNF-alpha -Induced Cell Death. Science 274: 782-784 [Abstract] [Full Text]
Kainulainen, V., Nelimarkka, L., Jarvelainen, H., Laato, M., Jalkanen, M., Elenius, K. (1996). Suppression of Syndecan-1 Expression in Endothelial Cells by Tumor Necrosis Factor-alpha. J. Biol. Chem. 271: 18759-18766 [Abstract] [Full Text]
Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., Rehemtulla, A. (2000). Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 97: 1754-1759 [Abstract] [Full Text]